Abbvie Inc.

Abbott Laboratories Corporation

Smithkline Beecham Corporation

Glaxosmithkline LLC

Abbvie Bahamas Limited

Eric Allen Schmitt

Jonathan Miller

Geoff G Z Zhang

Yi Gao

Michele Catherine Rizzolio

Bobby Neal Glover

Barry Riddle Sickles

Lian-Feng Huang

Robert William Lancaster

Rajeev Gokhale

Stacey Todd Long

Bernd Liepold

Thomas Kessler

Steven L Krill

Nathaniel Catron

James J Fort

Devalina Law

Yi Shi

Ping Gao

Ping Tong

Nancy E Sever

Carl M Knable

Mark Costello

John B Morris

Drazen Kostelac

Mirko Pauli

Peter Hoelig

Anna Moosmann

Fatih Durak

Karin Rosenblatt

Rodger F Henry

Yihong Qiu

Yeshwant D Sanzgiri

Deliang Zhou

Cristina M Fischer

Katherine R Heemstra

Ira S Buckner

Anthony Ralph Haight

Geoff G Zhang

William Porter

Michael G Fickes

Peter Hölig

Justin S Lafountaine

Adivaraha Jayasankar

David J Lindley

Lloyd Dias

Hao Hou

David Beno

Ameesha Patel

Huailiang Wu

Susan George

Nathaniel D Catron

Peter Holig

William R Porter

Justin Lafountaine

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Solid dispersions containing an apoptosis-inducing agent

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.

Formulations of phenyl uracil compounds

The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-&#x3b2;-L-ribofuranosyl-1H-benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.

Crystalline forms of an antiviral benzimidazole compound

A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

Inhibitors of crystallization in a solid dispersion

A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ABT-263 capsule

An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Stabilized lipid formulation of apoptosis promoter

A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.

Solid dispersions containing kinase inhibitors

The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-&#x3b2;-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.

N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.

N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1

N-((2Z)-2-((4-Hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide Crystalline Form 2, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.

N-((2Z)-2-((4-hydroxyphenyl) amino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2

A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.

Solid dispersion pharamaceutical formulations

The invention relates to Form physical forms of 5,6-dichloro-2-(isopropylamino)-1-&#x3b2;-L-ribofuranosyl-1H-benzimidazole, pharmaceutical compositions comprising the same, and their use in medical therapy.

Growing community of inventors

Libertyville, IL, United States of America

Eric Allen Schmitt